JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

28.74 2.2

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

28.54

Máximo

28.8

Métricas clave
By Trading Economics
Ingresos	-85K 53M
Ventas	4.2M 153M
P/B Media del Sector	17.423 67.147
BPA	0.68
Margen de beneficios	34.53
Empleados	182
EBITDA	612K 81M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+19.21% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	611M 3.6B
Apertura anterior	26.54
Cierre anterior	28.74

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 may 2026, 23:43 UTC

Noticias de Eventos Importantes

New Zealand's Unemployment Rate Falls in 1Q

5 may 2026, 23:20 UTC

Acciones populares

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 may 2026, 21:48 UTC

Ganancias

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 may 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

5 may 2026, 23:39 UTC

Charlas de Mercado

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 may 2026, 22:26 UTC

Charlas de Mercado

AMD Data-Center Business Continues to Surge -- Market Talk

5 may 2026, 22:20 UTC

Charlas de Mercado

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 may 2026, 22:08 UTC

Ganancias

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 may 2026, 22:07 UTC

Ganancias

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 may 2026, 21:48 UTC

Ganancias

Pan American Silver 1Q Rev $1.2B >PAAS

5 may 2026, 21:42 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:38 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:30 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:29 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:26 UTC

Ganancias

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q EPS 39c >ALC.EB

5 may 2026, 21:25 UTC

Ganancias

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 may 2026, 21:24 UTC

Ganancias

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 may 2026, 21:18 UTC

Ganancias

Mistras Backs 2026 Rev $730M-$750M >MG

5 may 2026, 21:17 UTC

Ganancias

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 may 2026, 21:15 UTC

Ganancias

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 may 2026, 21:12 UTC

Ganancias

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 may 2026, 21:11 UTC

Ganancias

SSR Mining 1Q Rev $581.8M >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 may 2026, 21:10 UTC

Ganancias

SSR Mining 1Q EPS $1.16 >SSRM

5 may 2026, 21:08 UTC

Ganancias

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 may 2026, 21:01 UTC

Ganancias

Intact Financial 1Q EPS C$4.12 >IFC.T

5 may 2026, 21:01 UTC

Acciones populares

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

5 may 2026, 20:59 UTC

Ganancias

Palantir Beat on Every Key Earnings Metric. Why Its Stock Still Fell. -- Barrons.com

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

19.21% repunte

Estimación a 12 Meses

Media 34.5 USD 19.21%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.